Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Biomarker Discovery
• Hepatocellular Carcinoma Research

Background:

• Liver cancer incidence and mortality rates are increasing globally.
• Hepatocellular carcinoma (HCC) diagnosis often occurs at advanced stages, leading to poor prognoses.
• Early-stage HCC is curable with surgery, but high rates of postoperative recurrence persist.

Purpose of the Study:

• To review recent advancements in liquid biopsy biomarkers for hepatocellular carcinoma (HCC).
• To highlight the need for biomarkers to guide HCC therapy sequencing and improve patient outcomes.
• To discuss the role of liquid biopsies in early detection, minimal residual disease monitoring, and treatment response prediction.

Main Methods:

• Literature review of recent studies on liquid biopsy biomarkers in HCC.
• Analysis of current challenges in HCC management and the potential of novel biomarkers.
• Focus on biomarkers for early detection, recurrence monitoring, and treatment efficacy.

Main Results:

• Liquid biopsies offer potential for early HCC detection, surpassing current diagnostic methods.
• Biomarkers can identify minimal residual disease post-treatment, indicating recurrence risk.
• Liquid biopsies may predict patient response to various HCC therapies, aiding personalized treatment strategies.

Conclusions:

• Liquid biopsy biomarkers are crucial for improving early detection of liver cancer.
• Monitoring minimal residual disease with liquid biopsies can inform timely interventions.
• Biomarkers are essential for optimizing treatment sequencing in HCC to maximize efficacy and minimize toxicity.